Measurement of narcolepsy symptoms: The Narcolepsy Severity Scale.
Dauvilliers YFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France. ydauvilliers@yahoo.fr.
Beziat SFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Pesenti CFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Lopez RFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Barateau LFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Carlander BFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Luca GFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Tafti MFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Morin CMFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Billiard MFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
Jaussent IFrom CHU Montpellier (Y.D., S.B., C.P., R.L., L.B., B.C., M.B.), Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France; Center for Integrative Genomics (G.L., M.T.), University of Lausanne; Centre Neuchâtelois de Psychiatrie (G.L.), Neuchâtel; Center for Investigation and Research in Sleep (M.T.), Lausanne University Hospital, Switzerland; Department of Psychology (C.M.M.), Université Laval, Quebec City, Quebec, Canada; Inserm (Y.D., S.B., C.P., R.L., I.J.), U1061; and Université Montpellier (Y.D., S.B., C.P., R.L., I.J.), France.
English
OBJECTIVE To validate the Narcolepsy Severity Scale (NSS), a brief clinical instrument to evaluate the severity and consequences of symptoms in patients with narcolepsy type 1 (NT1).
METHODS A 15-item scale to assess the frequency and severity of excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nighttime sleep was developed and validated by sleep experts with patients' feedback. Seventy untreated and 146 treated adult patients with NT1 were evaluated and completed the NSS in a single reference sleep center. The NSS psychometric properties, score changes with treatment, and convergent validity with other clinical parameters were assessed.
RESULTS The NSS showed good psychometric properties with significant item-total score correlations. The factor analysis indicated a 3-factor solution with good reliability, expressed by satisfactory Cronbach α values. The NSS total score temporal stability was good. Significant NSS score differences were observed between untreated and treated patients (dependent sample, 41 patients before and after sleep therapy; independent sample, 29 drug-free and 105 treated patients). Scores were lower in the treated populations (10-point difference between groups), without ceiling effect. Significant correlations were found among NSS total score and daytime sleepiness (Epworth Sleepiness Scale, Mean Sleep Latency Test), depressive symptoms, and health-related quality of life.
CONCLUSIONS The NSS can be considered a reliable and valid clinical tool for the quantification of narcolepsy symptoms to monitor and optimize narcolepsy management.